Semaglutide in type 2 diabetes with chronic kidney disease at high risk progression—real-world clinical practice
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Semaglutide in type 2 diabetes with chronic kidney disease at high risk progression—real-world clinical practice
Authors
Keywords
-
Journal
Clinical Kidney Journal
Volume -, Issue -, Pages -
Publisher
Oxford University Press (OUP)
Online
2022-04-11
DOI
10.1093/ckj/sfac096
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- TO002REDUCTION IN THE RATE OF EGFR DECLINE WITH SEMAGLUTIDE VS PLACEBO: A POST HOC POOLED ANALYSIS OF SUSTAIN 6 AND PIONEER 6
- (2020) Katherine Tuttle et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial
- (2019) Bernard Zinman et al. Lancet Diabetes & Endocrinology
- SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA
- (2019) Pantelis Sarafidis et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
- (2019) Hertzel C Gerstein et al. LANCET
- Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial
- (2019) Ofri Mosenzon et al. Lancet Diabetes & Endocrinology
- Efficacy and safety of once-weekly semaglutide 1.0 mg vs once-daily liraglutide 1.2 mg as add-on to 1–3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10)
- (2019) M.S. Capehorn et al. DIABETES & METABOLISM
- Semaglutide Added to Basal Insulin in Type 2 Diabetes (SUSTAIN 5): A Randomized, Controlled Trial
- (2018) Helena W Rodbard et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial
- (2018) Richard E Pratley et al. Lancet Diabetes & Endocrinology
- ¿Serán las nuevas moléculas efectivas en protección renal y cardiovascular en la diabetes mellitus y la enfermedad renal diabética?
- (2018) Alberto Martinez Martinez-Castelao et al. NEFROLOGIA
- Intensified multifactorial intervention in type 2 diabetics with microalbuminuria leads to long-term renal benefits
- (2017) Jens Oellgaard et al. KIDNEY INTERNATIONAL
- Guía ERBP sobre la diabetes en la enfermedad renal crónica estadio 3B o mayor: ¿metformina para todos?
- (2017) Alberto Martínez-Castelao et al. NEFROLOGIA
- Clinical Practice Guideline on management of older patients with chronic kidney disease stage 3b or higher (eGFR
- (2017) Ken Farrington et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Liraglutide and Renal Outcomes in Type 2 Diabetes
- (2017) Johannes F.E. Mann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial
- (2017) Bo Ahrén et al. Lancet Diabetes & Endocrinology
- Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial
- (2017) Vanita R Aroda et al. Lancet Diabetes & Endocrinology
- Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials
- (2017) Sophia Zoungas et al. Lancet Diabetes & Endocrinology
- Management of patients with diabetes and CKD: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference
- (2016) Vlado Perkovic et al. KIDNEY INTERNATIONAL
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and Safety of Liraglutide Versus Placebo as Add-on to Glucose-Lowering Therapy in Patients With Type 2 Diabetes and Moderate Renal Impairment (LIRA-RENAL): A Randomized Clinical Trial
- (2015) Melanie J. Davies et al. DIABETES CARE
- Semaglutide, a once-weekly human GLP-1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol/levonorgestrel
- (2015) Christoph Kapitza et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
- (2015) Marc A. Pfeffer et al. NEW ENGLAND JOURNAL OF MEDICINE
- GLP-1 Receptor Localization in Monkey and Human Tissue: Novel Distribution Revealed With Extensively Validated Monoclonal Antibody
- (2014) Charles Pyke et al. ENDOCRINOLOGY
- Patient-Reported and Actionable Safety Events in CKD
- (2014) J. S. Ginsberg et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Kidney Disease and Increased Mortality Risk in Type 2 Diabetes
- (2013) M. Afkarian et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Association Between Glycemic Control and Adverse Outcomes in People With Diabetes Mellitus and Chronic Kidney Disease
- (2011) Sabin Shurraw ARCHIVES OF INTERNAL MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More